What is Zacks Research’s Estimate for BIO Q3 Earnings?

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Stock analysts at Zacks Research decreased their Q3 2025 earnings estimates for Bio-Rad Laboratories in a research report issued to clients and investors on Thursday, March 6th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $2.72 per share for the quarter, down from their previous estimate of $2.94. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2025 earnings at $3.09 EPS, Q4 2026 earnings at $3.22 EPS, FY2026 earnings at $12.34 EPS and FY2027 earnings at $9.27 EPS.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%.

Several other research firms have also recently weighed in on BIO. Royal Bank of Canada reissued an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Wells Fargo & Company decreased their price objective on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Stock Down 0.8 %

BIO opened at $258.37 on Friday. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The firm has a 50 day moving average price of $322.58 and a 200-day moving average price of $331.14. Bio-Rad Laboratories has a twelve month low of $248.22 and a twelve month high of $387.99. The stock has a market capitalization of $7.24 billion, a price-to-earnings ratio of -3.97 and a beta of 0.98.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Venturi Wealth Management LLC boosted its position in shares of Bio-Rad Laboratories by 2,175.0% in the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock worth $30,000 after purchasing an additional 87 shares during the period. GeoWealth Management LLC boosted its holdings in Bio-Rad Laboratories by 342.9% in the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company’s stock worth $31,000 after buying an additional 72 shares during the period. Gladius Capital Management LP bought a new stake in Bio-Rad Laboratories during the third quarter valued at about $32,000. Picton Mahoney Asset Management lifted its position in shares of Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 35 shares in the last quarter. Finally, Asset Planning Inc bought a new position in shares of Bio-Rad Laboratories in the fourth quarter worth about $33,000. 65.24% of the stock is currently owned by institutional investors.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.